Visually Enhanced Education About Prostate Cancer

Status Completed

Clinical Trial Summary

This randomized clinical trial studies how well visually enhanced education works in improving prostate cancer and treatment knowledge in patients with prostate cancer that has not spread to other places in the body. Visually enhanced education includes pictures, drawings, and photos, may help doctors better convey information about radiation and prostate cancer to patients.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. Our goal is to conduct a randomized controlled trial to determine the impact of a visual presentation in the context of a radiation oncologist's discussion with patient during consultation on patient satisfaction at end of consultation visit and at end of treatment, on anxiety at start of treatment, on decision regret following treatment, and on perception of side effects following treatment. Of note, the attending radiation oncologist will be responsible for reviewing the Powerpoint presentation with the patient, taking time to answer any questions that the patient has

OUTLINE: Patients are randomized into 1 of 2 arms.

ARM A (STANDARD EDUCATION): Patients receive a standard prostate cancer radiation oncology consultation.

ARM B (VISUAL ENHANCED EDUCATION): Patients receive a visually enhanced prostate cancer educational Powerpoint presentation including prostate anatomy, pathologic results, surgical options, radiation therapy, and prognosis with pictographs during radiation oncology consultation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02846870
Study type	Interventional
Source	Vanderbilt-Ingram Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	September 2016
Completion date	August 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02217709` - Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer	Phase 2
Completed	`NCT00103194` - Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer	Phase 2
Completed	`NCT01385059` - Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer	Phase 2
Terminated	`NCT00536991` - Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Phase 1/Phase 2
Completed	`NCT00074022` - GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04589468` - Researching the Effect of Exercise on Cancer	N/A
Active, not recruiting	`NCT01823562` - Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery	Phase 1
Active, not recruiting	`NCT01923506` - Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery	Phase 1
Recruiting	`NCT02605226` - Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer	N/A
Completed	`NCT00589472` - Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer	Phase 2
Active, not recruiting	`NCT02278185` - Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer	Phase 2
Completed	`NCT01117935` - Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer	N/A
Completed	`NCT01731912` - Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer	N/A
Withdrawn	`NCT00996749` - Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer	N/A
Completed	`NCT01656304` - Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy	Phase 2
Recruiting	`NCT03880422` - Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors	N/A
Completed	`NCT02048150` - Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer	Phase 1
Withdrawn	`NCT01555632` - Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy	N/A
Completed	`NCT00956163` - Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer	Phase 0
Completed	`NCT01023061` - Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer	Phase 2